FDA Approves Rivastigmine Patch—But Rebukes Misleading Marketing of Oral Form

FDA, Food and Drug Administration, rivastigmine, patch, Alzheimer, Alzheimer's, dementia, neurology, neurologic disorder, Exelon, Novartis, cholinesterase, Division of Drug Marketing, Advertising, and Communications, DDMAC, misleading, marketing, advertising, rebuke, rebukesFDA, Food and Drug Administration, rivastigmine, patch, Alzheimer, Alzheimer's, dementia, neurology, neurologic disorder, Exelon, Novartis, cholinesterase, Division of Drug Marketing, Advertising, and Communications, DDMAC, misleading, marketing, advertising, rebuke, rebukes

FDA, Food and Drug Administration, rivastigmine, patch, Alzheimer, Alzheimer's, dementia, neurology, neurologic disorder, Exelon, Novartis, cholinesterase, Division of Drug Marketing, Advertising, and Communications, DDMAC, misleading, marketing, advertising, rebuke, rebukesFDA, Food and Drug Administration, rivastigmine, patch, Alzheimer, Alzheimer's, dementia, neurology, neurologic disorder, Exelon, Novartis, cholinesterase, Division of Drug Marketing, Advertising, and Communications, DDMAC, misleading, marketing, advertising, rebuke, rebukes

FDA, Food and Drug Administration, rivastigmine, patch, Alzheimer, Alzheimer's, dementia, neurology, neurologic disorder, Exelon, Novartis, cholinesterase, Division of Drug Marketing, Advertising, and Communications, DDMAC, misleading, marketing, advertising, rebuke, rebukesFDA, Food and Drug Administration, rivastigmine, patch, Alzheimer, Alzheimer's, dementia, neurology, neurologic disorder, Exelon, Novartis, cholinesterase, Division of Drug Marketing, Advertising, and Communications, DDMAC, misleading, marketing, advertising, rebuke, rebukes